Kaempferol: A potential agent in the prevention of colorectal cancer.
Hamid Reza NejabatiLeila RoshangarPublished in: Physiological reports (2022)
Colorectal cancer (CRC) is the third most prevalent cancer in relation to incidence and mortality rate and its incidence is considerably increasing annually due to the change in the dietary habit and lifestyle of the world population. Although conventional therapeutic options, such as surgery, chemo- and radiotherapy have profound impacts on the treatment of CRC, dietary therapeutic agents, particularly natural products have been regarded as the safest alternatives for the treatment of CRC. Kaempferol (KMP), a naturally derived flavonol, has been shown to reduce the production of reactive oxygen species (ROS), such as superoxide ions, hydroxyl radicals, and reactive nitrogen species (RNS), especially peroxynitrite. Furthermore, this flavonol inhibits xanthine oxidase (XO) activity and increases the activities of catalase, heme oxygenase-1 (HO), and superoxide dismutase (SOD) in a wide range of cancer and non-cancer cells. Based on several studies, KMP is also a hopeful anticancer which carries out its anticancer action via suppression of angiogenesis, stimulation of apoptosis, and cell cycle arrest. Due to various applications of KMP as an anticancer flavonol, this review article aims to highlight the current knowledge regarding the role of KMP in CRC.
Keyphrases
- cell cycle arrest
- cell death
- reactive oxygen species
- papillary thyroid
- risk factors
- pi k akt
- minimally invasive
- healthcare
- squamous cell
- cardiovascular disease
- hydrogen peroxide
- combination therapy
- metabolic syndrome
- oxidative stress
- early stage
- physical activity
- photodynamic therapy
- dna damage
- endoplasmic reticulum stress
- squamous cell carcinoma
- percutaneous coronary intervention
- lymph node metastasis
- weight loss
- uric acid
- coronary artery bypass
- nitric oxide
- coronary artery disease
- endothelial cells
- human health
- intellectual disability
- quantum dots
- risk assessment
- cardiovascular events
- amyotrophic lateral sclerosis
- smoking cessation